We also postulated that APOE2 and APOE4 allelic dose would have a more profound impact on Alzheimer’s dementia odds ratios (ORs) in neuropathologically confirmed than in unconfirmed cases and controls due to the exclusion of clinically diagnosed cases who did not meet the neuropathological criteria for AD and unimpaired controls who met the criteria for AD, since misclassified cases and controls could dilute and/or bias OR estimates in the unconfirmed group. Here, APOE is linked to Alzheimer disease.